Trial at a glance
What medical condition is being studied? Chronic Inflammatory Demyelinating Polyradiculoneuropathy
What is the trial testing? HYQVIA; 0.25% albumin placebo solution with rHuPH20; IGIV
How many participants are being enrolled? 232
When is the trial being conducted? -
Key requirements
Sex
All
Age
From 18 Years
Accepts Healthy Volunteers?
No
Trial Details / Participation Requirements
CLICK TO EXPANDCLICK TO COLLAPSE
Trial phase: Phase 3
Trial Type: Interventional
Trial Arms/Groups or Cohorts:
Epoch 1: HYQVIA/HyQvia: Participants will receive SC HYQVIA/HyQvia at a dose of 80 Unit per gram (U/g) immunoglobulin (IgG) which will be same as the participants pre-randomization monthly equivalent IgG dose (or at matching infusion volume for participants in the placebo group) when administered at a dosing frequency of every 2, 3, or 4 weeks for 6 months or until relapse.
Epoch 1: Placebo with rHuPH20: Participants will receive sequential 0.25% albumin placebo with rHuPH20 at a dose of 80U/g IgG subcutaneously for 6 months or until relapse. Dosing regimen for placebo treatment will be the same as the participant's pre-randomization monthly equivalent IgG infusion volume when administered every 2, 3, or 4 weeks.
Epoch 2: IGIV: Participants will recieve an induction dose of 2 Gram per kilogram (g/kg) Intravenous immunoglobulin G (IGIV), followed by maintenance infusions at the same monthly dose as the participant's pre-randomization IgG dose, every 3 weeks for 6 months or until relapse.
Intervention: HYQVIA; 0.25% albumin placebo solution with rHuPH20; IGIV
Primary Outcome Measure(s):
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Pre-SC Baseline Week 1 [Time Frame: Pre-SC Baseline (Week 1)]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 5 [Time Frame: Week 5]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 9 [Time Frame: Week 9]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 13 [Time Frame: Week 13]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 15 [Time Frame: Week 15]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 19 [Time Frame: Week 19]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 23 [Time Frame: Week 23]
Epoch 1: Relapse Rate on Every 2 Weeks Dosing Regimen (Q2W) at Week 27 (End of Epoch 1 Treatment [EOE1T])/Unscheduled relapse visit assessment (UV)/Early Termination (ET) [Time Frame: Week 27 (EOET1)/UV/ET]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Pre-SC Baseline [Time Frame: Pre-SC Baseline]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 5 [Time Frame: Week 5]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 8 [Time Frame: Week 8]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 11 [Time Frame: Week 11]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 14 [Time Frame: Week 14]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 17 [Time Frame: Week 17]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 20 [Time Frame: Week 20]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 23 [Time Frame: Week 23]
Epoch 1: Relapse Rate on Every 3 Weeks Dosing Regimen (Q3W) at Week 26 (EOE1T)/Unscheduled relapse visit assessment (UV)/Early Termination (ET) [Time Frame: Week 26 (EOE1T)/UV/ET]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Pre-SC Baseline [Time Frame: Pre-SC Baseline]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 5 [Time Frame: Week 5]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 8 [Time Frame: Week 8]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 12 [Time Frame: Week 12]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 16 [Time Frame: Week 16]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 20 [Time Frame: Week 20]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 24 [Time Frame: Week 24]
Epoch 1: Relapse Rate on Every 4 Weeks Dosing Regimen (Q4W) at Week 28 (EOET1)/Unscheduled relapse visit assessment (UV)/Early Termination (ET) [Time Frame: Week 28 (EOET1)/UV/ET]
Epoch 2: Responder Rate on Every 3 Weeks Dosing Regimen at Pre-Baseline (Week 1) [Time Frame: Pre-IV Baseline (Week 1)]
Epoch 2: Responder Rate on Every 3 Weeks Dosing Regimen up to 6 Months (End of Epoch 2 Treatment [EOE2T])/Unscheduled visit assessment (UV)/Early Termination [Time Frame: Up to 6 Months/UV/ET]
Secondary Outcome Measure(s):
Epoch 1: Time to Relapse [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Change From Pre-Subcutaneous (SC) Treatment Baseline in Rasch-built Overall Disability Scale (R-ODS) Score [Time Frame: Pre-subcutaneous (SC) treatment baseline, then weekly through Epoch 1 (up to 6 months); Unscheduled relapse visit assessment; & if early termination occurs.]
Epoch 1: Number of Participants Experiencing Any Treatment-Emergent Serious and/or Non-serious Adverse Events (SAEs and/or AEs), Regardless of Causality [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants Experiencing Causally Related Serious And/or Non-Serious Adverse Events (SAEs And/or AEs) [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants With Serious And/Or Non-serious Adverse Reactions (ARs) Plus Suspected ARs [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Infusions Associated with Treatment-emergent Serious And/Or Non-serious Adverse Events (SAEs And/Or AEs), Regardless of Causality [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Infusions Associated with Causally Related Serious And/Or Non-serious Adverse Events (SAEs And/Or AEs) [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Infusions Temporally Associated with Adverse Events (AEs) [Time Frame: During an infusion or within 72 hours after completion of an infusion]
Epoch 1: Number of Infusions Associated with Serious And/Or Non-serious Adverse Reactions (ARs) plus Suspected ARs [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Infusions Associated with Treatment-emergent Systemic Adverse Events (AEs) [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Infusions Associated with Treatment-emergent Local Infusion Site Reactions [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Infusions for Which the Infusion Rate Was Reduced And/Or the Infusion Was Interrupted or Stopped Due to Intolerability And/Or Adverse Events (AEs) [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events Per Infusion [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events per Participant [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events per Participant-year [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed As Number of Events Per Infusion [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed As Number of Events Per Participant [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed as Number of Events per Participant-year [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected Ars, Expressed as Number of Events per Infusion [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events per Participant [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events per Participant-Year [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 1: Number of Participants Who Develop Binding And/Or Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20) [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 2: Number of Participants Experiencing Any Treatment-emergent Serious And/Or Non-serious Adverse Events (SAEs And/Or AEs), Regardless of Causality [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants Experiencing Causally Related Serious And/Or Non-serious Adverse Events (SAEs And/Or AEs) [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Participants with Serious And/Or Non-serious Adverse Reactions (ARs) plus Suspected ARs [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Infusions Associated with Treatment-emergent Serious And/Or Non-serious Adverse Events (SAEs And/Or AEs), Regardless of Causality [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Infusions Associated With Causally Related Serious And/Or Non-serious Adverse Events (SAEs And/Or AEs) [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Infusions Temporally Associated with Adverse Events (AEs) [Time Frame: During an infusion or within 72 hours after completion of an infusion]
Epoch 2: Number of Infusions Associated with Serious And/Or Non-serious Adverse Reactions (ARs) plus Suspected ARs [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Infusions Associated with Treatment-emergent Systemic Adverse Events (AEs) [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Infusions Associated with Treatment-emergent Local Infusion Site Reactions [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Number of Infusions for Which the Infusion Rate Was Reduced And/Or the Infusion Was Interrupted or Stopped Due to Intolerability And/Or Adverse Events (AEs) [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events Per Infusion [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events Per Participant [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Events (AEs), Regardless of Causality, Expressed as Number of Events Per Participant-year [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed As Number of Events Per Infusion [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed as Number of Events Per Participant [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Causally Related Systemic and Local Adverse Events (AEs), Expressed as Number of Events Per Participant-Year [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected Ars, Expressed as Number of Events Per Infusion [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events Per Participant [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 2: Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected ARs, Expressed as Number of Events Per Participant-Year [Time Frame: Throughout Epoch 2, up to 6 months]
Epoch 1: Proportion of Participants Who Experience a Worsening of Functional Disability [Time Frame: Throughout Epoch 1, up to 6 months]
Epoch 2: Proportion of Participants With Clinically Meaningful Improvement in Functional Ability [Time Frame: Throughout Epoch 2, up to 6 months]
Entry Criteria:
Inclusion Criteria:
1. Documented diagnosis of definite or probable Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) (focal atypical CIDP and pure sensory atypical CIDP will be excluded) consistent with European Federation of Neurological Societies/Peripheral
Nerve Society (EFNS/PNS) 2010 criteria.
2. Participant has responded to IgG treatment in the past (partial or complete resolution of neurological symptoms and deficits), and must currently be on stable doses of intravenous immunoglobulin G (IGIV) treatment within the dose range equivalent to a cumulative monthly dose of 0.4 to 2.4 g/kg BW (inclusive) administered intravenously for at least 12 weeks prior to screening. The dosing interval of IGIV treatment must be between 2 and 6 weeks (inclusive). Variations in the dosing interval of up to ± 7 days or monthly dose amount of up to ± 20% between participant’s pre-study IgG infusions are within acceptable limits
3. Inflammatory Neuropathy Cause and Treatment disability scale (INCAT) disability score between 0 and 7 (inclusive). Participants with INCAT scores of 0, 1, or 2 (if at least 1 point is from an upper extremity) must have a history of significant disability - ie, INCAT disability score of 2 (must be exclusively from the lower extremities) or greater documented in the medical record.
4. If female of childbearing potential, the participant must have a negative pregnancy test at screening and agree to employ a highly effective contraceptive measure throughout the course of the study and for at least 30 days after the last administration of investigational product.
5. Participant is willing and able to sign an Informed Consent Form (ICF).
6. Participant is willing and able to comply with the requirements of the protocol.
Exclusion Criteria:
1. Focal atypical CIDP or pure sensory atypical CIDP.
2. Any neuropathy of other causes, including:
a. Hereditary demyelinating neuropathies, such as hereditary sensory and motor neuropathy (HSMN) (Charcot-Marie-Tooth [CMT] disease), multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), and hereditary sensory and autonomic neuropathies (HSANs)
b. Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria; systemic lupus erythematosus; polyneuropathy, organomegaly, endocrinopathy or edema, M-protein, skin changes (POEMS) syndrome; osteosclerotic myeloma; diabetic and non-diabetic lumbosacral radiculoplexus neuropathy; lymphoma, and amyloidosis
c. Multifocal motor neuropathy (MMN)
d. Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy
3. Immunoglobulin M (IgM) paraproteinemia, including IgM monoclonal gammopathy with high titer antibodies to myelin-associated glycoprotein
4. Prominent sphincter disturbance.
5. Central demyelinating disorders (eg, multiple sclerosis).
6. Any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of CIDP or outcome measures (eg, arthritis, stroke, Parkinson’s disease, and diabetic peripheral neuropathy)
(Participants with clinically diagnosed diabetes mellitus who do not have diabetic peripheral neuropathy, who have adequate glycemic control with Hemoglobin A1C; also known as glycosylated or glycated hemoglobin (HbA1C) of <7.5% at screening, and who agree to maintain adequate glycemic control during the study are allowed.)
7. Congestive heart failure (New York Heart Association (NYHA) Class III/IV), unstable angina, unstable cardiac arrhythmias, or uncontrolled hypertension (ie, diastolic blood pressure >100 mmHg and/or systolic blood pressure >160 mmHg).
8. History of deep vein thrombosis or thromboembolic events (eg, cerebrovascular accident, pulmonary embolism) in the past 12 months.
9. Condition(s) which could alter protein catabolism and/or IgG utilization (eg, protein-losing enteropathies, nephrotic syndrome).
10. Known history of chronic kidney disease, or glomerular filtration rate (GFR) of <60 mL/min/1.73m^2 estimated based on CKD-EPI equation (2009).
11. Participant with active malignancy requiring chemotherapy and/or radiotherapy, or history of malignancy with less than 2 years of complete remission prior to screening. Exceptions are: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment.
12. Clinically significant anemia or hemoglobin (Hgb) level of <10.0 g/dL at screening.
13. Hypersensitivity or adverse reactions (eg, urticaria, breathing difficulty, severe hypotension, or anaphylaxis) to human blood products such as human IgG, albumin, or other blood components.
14. Known allergy to hyaluronidase of human (including recombinant human hyaluronidase) or animal origin (such as bee or wasp venom).
15. Known history of or immunoglobulin A (IgA) deficiency (<8 mg/dL) at screening.
16. Abnormal laboratory values at screening:
a. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2.5x upper limit of normal (ULN)
b. Platelet count <100,000 cells/µL
c. Absolute neutrophil count (ANC) <1000 cells/µL
17. Ongoing/active infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) Type 1/2 infection.
18. The participant has received or is currently receiving treatment with immunomodulatory/ immunosuppressive agents within 6 months prior to screening.
19. Participant has received or is currently receiving treatment with corticosteroids within 3 months prior to screening. The following exceptions for prednisolone or its equivalent are allowed: stable dosages of low-dose systemic corticosteroids (≤10 mg prednisolone/day or its equivalent) and non-systemic corticosteroids (eg, topical, ophthalmic, or inhaled glucocorticoids). In addition and for the purpose of treating AE or non-CIDP intercurrent disease, a single corticosteroid dose >10 mg prednisolone or a single short term course of ≤ to 7 days (such as Methylprednisolone Dose Pack) within 3 months prior to screening is allowed.
20. Participant has undergone plasma exchange within 3 months prior to screening.
21. The participant has any disorder or condition that in the investigator’s judgment may impede the participant’s participation in the study, pose increased risk to the participant, or confound the results of the study.
22. The participant is nursing or intends to begin nursing during the course of the study.
23. Participation in another clinical study involving an investigational product and/or device within 30 days prior to enrollment, or planned participation in another clinical study during the course of this study.
24. The participant is a family member or employee of the investigator.
Trial Locations
RESULTS
Barrow Neurological Institute
350 W Thomas Rd, Phoenix, AZ 85013, USA
Site Contact
Recruiting
5,802 miles (9,337 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Regents of the University of colorado
13001 E 17th Pl ste f-428, Aurora, CO 80045, USA
Site Contact
Recruiting
5,812 miles (9,353 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Immunoe Research Centers
6801 S Yosemite St, Centennial, CO 80112, USA
Site Contact
Recruiting
5,817 miles (9,362 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
University of Kansas Medical Center Research Institute, Inc.
3901 Rainbow Blvd, Kansas City, KS 66160, USA
Site Contact
Recruiting
6,221 miles (10,011 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Rutgers New Jersey Medical School
185 S Orange Ave, Newark, NJ 07103, USA
Site Contact
Recruiting
6,717 miles (10,810 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Recruiting
6,485 miles (10,436 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Austin Neuromuscular Center
3901 Medical Pkwy #300, Austin, TX 78756, USA
Site Contact
Recruiting
6,559 miles (10,555 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
University Texas Physicians CAR
6410 Fannin St, Houston, TX 77030, USA
Site Contact
Recruiting
6,682 miles (10,754 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Instituto de Neurologia de Curitiba - Hospital Ecoville
Rua Jeremias Maciel Perretto, 300 - Campo Comprido, Curitiba - PR, 81210-310, Brazil
Recruiting
11,547 miles (18,583 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
LHSC - University Hospital
339 Windermere Rd, London, ON N6A 5A5, Canada
Recruiting
6,405 miles (10,307 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Clinical Hospital Centre Rijeka
Krešimirova ul. 42, 51000, Rijeka, Croatia
Site Contact
Recruiting
5,805 miles (9,343 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Clinical Hospital Centar Zagreb
Kišpatićeva ul. 12, 10000, Zagreb, Croatia
Site Contact
Recruiting
5,729 miles (9,219 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
CHU de Nice Hôpital Pasteur 2
30 Voie Romaine, 06000 Nice, France
Site Contact
Recruiting
6,115 miles (9,842 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hôpital de la Timone
278 Rue Saint-Pierre, 13005 Marseille, France
Site Contact
Recruiting
6,195 miles (9,971 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Universitaetsmedizin Goettingen
Robert-Koch-Straße 40, 37075 Göttingen, Germany
Site Contact
Recruiting
5,614 miles (9,035 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Universitaetsklinikum Leipzig AoeR
Liebigstraße 18, 04103 Leipzig, Germany
Site Contact
Recruiting
5,558 miles (8,944 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Recruiting
5,890 miles (9,479 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Instituto Nacional de Ciencias Médicas y Nutricion Dr. Salvador Zubiran
Vasco de Quiroga 15, Belisario Domínguez Secc 16, Tlalpan, 14080 Ciudad de México, CDMX, Mexico
Site Contact
Recruiting
7,054 miles (11,352 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
Jaczewskiego 8, 20-954 Lublin, Poland
Site Contact
Recruiting
5,252 miles (8,452 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego
Dr. Stefana Kopcińskiego 22, 90-001 Łódź, Poland
Site Contact
Recruiting
5,325 miles (8,570 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Clinical Center Nis
Bulevar Dr Zorana Đinđića 48, Niš 18000, Serbia
Site Contact
Recruiting
5,646 miles (9,087 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Universitari de Bellvitge
Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
Recruiting
6,402 miles (10,303 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Universitari Vall d'Hebron
Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain
Site Contact
Recruiting
6,396 miles (10,293 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Dokuz Eylul University Faculty of Medicine
İnciraltı, Otopark, 35330 Balçova/İzmir, Turkey
Recruitment Complete
5,676 miles (9,134 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Arizona Neuromuscular Research Center
4545 E Shea Blvd, Phoenix, AZ 85028, USA
Currently On Hold
5,801 miles (9,336 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
HonorHealth Neurology
3501 N Scottsdale Rd Ste. 280A, Scottsdale, AZ 85251, USA
Currently On Hold
5,808 miles (9,347 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
5,536 miles (8,909 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Forbes Norris Mda/als Ctr
1100 Van Ness Ave 6th Floor, San Francisco, CA 94109, USA
Site contact
Currently On Hold
5,160 miles (8,304 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
7,247 miles (11,663 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
William Beaumont Hospital
3601 W 13 Mile Rd, Royal Oak, MI 48073, USA
Currently On Hold
6,383 miles (10,272 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital for Special Surgery
Hospital for Special Surgery, 535 E 70th St, New York, NY 10021, USA
Currently On Hold
6,721 miles (10,816 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Wake Forest University
1834 Wake Forest Rd, Winston-Salem, NC 27109, USA
Currently On Hold
6,840 miles (11,007 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
6,541 miles (10,527 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Italiano
Pres. Tte. Gral. Juan Domingo Perón 4190, C1199 ABH, Buenos Aires, Argentina
Currently On Hold
11,472 miles (18,463 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Britanico de Buenos Aires
Perdriel 74, C1280 AEB, Buenos Aires, Argentina
Currently On Hold
11,475 miles (18,467 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Complejo Medico de la Policia Federal Argentina Churruca Visca
Uspallata 3400, C1437 CABA, Argentina
Currently On Hold
11,474 miles (18,465 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Instituto de Investigaciones Neurologicas Raul Carrea, FLENI
Montañeses 2325, C1428 AQK, Buenos Aires, Argentina
Currently On Hold
11,470 miles (18,460 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
HUAP - UFF - Hospital Universitario Antonio Pedro - Universidade Federal Fluminense
R. Marquês de Paraná, 303 - Centro, Niterói - RJ, 24033-900, Brazil
Currently On Hold
11,499 miles (18,505 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital das Clínicas da Faculdade de Medicina da UNICAMP
R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888, Brazil
Currently On Hold
11,440 miles (18,411 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital das Clínicas FMRP-USP
R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010, Brazil
Currently On Hold
11,315 miles (18,210 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Sao Paulo
Hospital São Paulo - Vila Clementino, São Paulo - SP, 04039-000, Brazil
Currently On Hold
11,499 miles (18,506 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
University of Alberta Hospital
8440 112 St NW, Edmonton, AB T6G 2B7, Canada
Currently On Hold
4,887 miles (7,864 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Toronto General Hospital
200 Elizabeth St, Toronto, ON M5G 2C4, Canada
Currently On Hold
6,414 miles (10,323 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia "IPS UNIVERSITARIA"
Cl. 69 ##51c-24, Medellín, Antioquia, Colombia
Currently On Hold
8,753 miles (14,086 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
University Hospital Centre "Sestre Milosrdnice"
Vinogradska cesta 29, 10000, Zagreb, Croatia
Currently On Hold
5,731 miles (9,223 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Fakultni nemocnice Brno
Jihlavská 340/20, 625 00 Brno-Bohunice-Brno-Starý Lískovec, Czechia
Currently On Hold
5,543 miles (8,920 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Fakultni nemocnice Ostrava
17. listopadu 1790, 708 00 Ostrava-Poruba, Czechia
Currently On Hold
5,460 miles (8,787 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
5,565 miles (8,957 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Groupe Hospitalier Pellegrin - Hôpital Pellegrin
Place Amélie Raba Léon, 33076 Bordeaux, France
Currently On Hold
6,273 miles (10,096 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hopital Neurologique Pierre Wertheimer
59 Boulevard Pinel, 69500 Bron, France
Currently On Hold
6,072 miles (9,772 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Universitaetsklinikum Essen
Hufelandstraße 55, 45147 Essen, Germany
Currently On Hold
5,699 miles (9,172 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Chaim Sheba Medical Center
Derech Sheba 2, Ramat Gan, Israel
Currently On Hold
5,612 miles (9,031 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
IRCCS Ospedale Casa Sollievo della Sofferenza
Viale Cappuccini, 1, 71013 San Giovanni Rotondo FG, Italy
Currently On Hold
5,947 miles (9,571 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Istituto Clinico Humanitas
Via Alessandro Manzoni, 56, 20089 Rozzano MI, Italy
Currently On Hold
5,968 miles (9,605 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Viale Oxford, 81, 00133 Roma RM, Italy
Currently On Hold
6,045 miles (9,728 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Azienda Ospedaliero Universitaria San Martino
Largo Rosanna Benzi, 10, 16132 Genova GE, Italy
Currently On Hold
6,027 miles (9,699 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Azienda Ospedaliera Universitaria Policlinico G. Martino
Via Consolare Valeria, 1, 98124 Messina ME, Italy
Currently On Hold
6,134 miles (9,871 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Casa di Cura del Policlinico
Via Giuseppe Dezza, 48, 20144 Milano MI, Italy
Currently On Hold
5,964 miles (9,598 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Fondazione Istituto Neurologico Casimiro Mondino
Via Mondino, 2, 27100 Pavia PV, Italy
Currently On Hold
5,978 miles (9,621 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Azienda Ospedaliero Universitaria Pisana
Via Roma, 67, 56126 Pisa PI, Italy
Currently On Hold
6,019 miles (9,687 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza
Piazzale Aldo Moro, 3/5, 00185 Roma RM, Italy
Currently On Hold
6,047 miles (9,731 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Corso Bramante, 88, 10126 Torino TO, Italy
Currently On Hold
6,031 miles (9,706 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
Piazzale Santa Maria della Misericordia, 15, 33100 Udine UD, Italy
Currently On Hold
5,805 miles (9,343 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Oslo Universitetssykehus HF, Ullevål
Bygg 19, Gaustad Sykehus, Sognsvannsveien 21, 0188 Oslo, Norway
Currently On Hold
5,152 miles (8,292 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
COPERNICUS Podmiot Leczniczy Sp. z o. o.,
Nowe Ogrody 1-6, 80-803 Gdańsk, Poland
Currently On Hold
5,227 miles (8,412 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
5,227 miles (8,411 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
5,627 miles (9,056 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
5,629 miles (9,059 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
5,537 miles (8,912 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital de la Santa Creu i Sant Pau
Carrer de Sant Quintí, 89, 08041 Barcelona, Spain
Currently On Hold
6,396 miles (10,293 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Universitario Virgen del Rocio
Av. Manuel Siurot, S/n, 41013 Sevilla, Spain
Currently On Hold
6,860 miles (11,040 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Pamukkale Uni. Med. Fac.
Çamlaraltı, Pamukkale Ünv. Hastane Yolu, 20070 Kınıklı/Pamukkale/Denizli, Turkey
Currently On Hold
5,619 miles (9,043 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty
Cerrahpaşa, Koca Mustafapaşa Cd. No:53 D:No:53, 34096 Fatih/İstanbul, Turkey
Currently On Hold
5,482 miles (8,822 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Selcuk Universitesi Selcuklu Tip Fakultesi Hastanesi
Ardıçlı, Akademi, Celal Bayar Cd. No:313, 42250 Selçuklu/Konya, Turkey
Currently On Hold
5,462 miles (8,791 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Celal Bayar University Medical Faculty
Şehit Prof. Dr. İlhan Varank Kampüsü, Yağcılar, 45140 Yunusemre/Manisa, Turkey
Currently On Hold
5,652 miles (9,095 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
5,926 miles (9,537 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
King's College Hospital
Denmark Hill, Herne Hill, London SE5 9RS, UK
Currently On Hold
5,872 miles (9,450 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Currently On Hold
5,816 miles (9,359 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Neurology Center of Las Vegas
2480 Professional Ct, Las Vegas, NV 89128, USA
5,543 miles (8,921 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
The Methodist Hospital Research Institute
6670 Bertner Ave, Houston, TX 77030, USA
6,683 miles (10,755 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
5,364 miles (8,633 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
5,269 miles (8,480 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Kepler Universitätsklinikum
Krankenhausstraße 9, 4020 Linz, Austria
5,657 miles (9,104 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
4,702 miles (7,566 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Recherche Sepmus, Inc.
4896 Boulevard Taschereau suite 250, Greenfield Park, QC J4V 2J2, Canada
6,437 miles (10,360 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Montreal Neurological Institute Clinical Research Unit
3801 Rue University, Montréal, QC H3A 2B4, Canada
6,433 miles (10,353 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Fundacion Oftalmologica de Santander - FOSCAL
Cl. 157 #23-99, Floridablanca, Santander, Colombia
8,798 miles (14,160 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Fundación Valle del Lili
Cra. 98 ## 18-49, Cali, Valle del Cauca, Colombia
8,878 miles (14,287 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Vseobecna fakultni nemocnice v Praze
U Nemocnice 499/2, 128 08 Praha 2-Nové Město, Czechia
5,563 miles (8,953 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
6,291 miles (10,124 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hopital Gui de Chauliac
80 Avenue Augustin Fliche, 38054 Montpellier, France
6,221 miles (10,012 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
CHU Clermont Ferrand - Hopital Gabriel Montpied
58 Rue Montalembert, 63000 Clermont-Ferrand, France
6,122 miles (9,852 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Bezirksklinikum Regensburg
Universitätsstraße 84, 93053 Regensburg, Germany
5,688 miles (9,154 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Universitaetsklinikum Giessen und Marburg GmbH Standort Marburg
Baldingerstraße, 35043 Marburg, Germany
5,685 miles (9,149 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Universitaetsmedizin Rostock
Gehlsheimer Str. 20, 18147 Rostock, Germany
5,421 miles (8,724 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Universitaetsklinikum Duesseldorf AoeR
Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225 Düsseldorf, Germany
5,718 miles (9,202 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Universitaetsklinikum Halle (Saale)
Ernst-Grube-Straße 40, 06120 Halle (Saale), Germany
5,562 miles (8,950 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Charité Universitaetsmedizin Berlin - Campus Charité Mitte
Charitépl. 1, 10117 Berlin, Germany
5,468 miles (8,800 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
251 General Air Force Hospital
Leof. Panagioti Kanellopoulou, Athina 115 25, Greece
5,826 miles (9,376 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
5,822 miles (9,370 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Tel Aviv Sourasky Medical Center
Weizmann St 6, Tel Aviv-Yafo, Israel
5,613 miles (9,033 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Dr. Angel Leaño
Av. Dr. Angel Leaño 500, Los Robles, 45200 Nuevo México, Jal., Mexico
6,787 miles (10,922 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Central Dr Ignacio Morones Prieto
Av Venustiano Carranza S/N, Zona Universitaria, 78290 San Luis, S.L.P., Mexico
6,829 miles (10,989 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Complejo Hospitalario Universitario de Santiago
Rúa da Choupana, s/n, 15706 Santiago de Compostela, A Coruña, Spain
6,583 miles (10,595 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Universitario Ramon y Cajal
M-607, km. 9, 100, 28034 Madrid, Spain
6,611 miles (10,640 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Universitario La Paz
Paseo de la Castellana, 261, 28046 Madrid, Spain
6,612 miles (10,640 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Universitari i Politecnic La Fe
Avinguda de Fernando Abril Martorell, 106, 46026 València, Valencia, Spain
6,583 miles (10,595 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Hospital Universitario Miguel Servet
Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain
6,469 miles (10,411 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Sahlgrenska universitetssjukhuset
Blå stråket 5, 413 45 Göteborg, Sweden
5,240 miles (8,433 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
5,878 miles (9,460 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Uludag University Medical Faculty
Özlüce Görükle Kampüsü, Özlüce, 16059 Nilüfer/Bursa, Turkey
5,519 miles (8,882 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Bezmialem Vakif
Adnan Menderes Bulvarı, Topkapı, Vatan Caddesi, 34093 Fatih/İstanbul, Turkey
5,481 miles (8,821 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
Marmara University Pendik Research and Training Hospital
Fevzi Çakmak, Muhsin Yazıcıoğlu Cd No:10, 34899 Pendik/İstanbul, Turkey
5,474 miles (8,810 km) awayfrom
æâ¥æŬ
æâ¥æŬ
View on Map
View all (113)
Trial Protocol ID: 161403
Back to Trial Summary